Hyperthermia for the treatment of patients with malignant germ cell tumors: A phase I/II study in ten children and adolescents with recurrent or refractory tumors

Cancer

Volumn 82, Issue 4, 1998, Pages 793-800

  Wessalowski, Rüdiger ^a   Kruck, Heidi ^a   Pape, Hildegard ^a   Kahn, Thomas ^a   Willers, Reinhart ^a   Göbel, Ulrich ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Chemotherapy; Cisplatin; Germ cell tumor; Microwave; Regional deep hyperthermia

Indexed keywords

CISPLATIN; COTRIMOXAZOLE; DROPERIDOL; ETOPOSIDE; IFOSFAMIDE; NYSTATIN; ONDANSETRON; PROMETHAZINE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CANDIDIASIS; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; ELECTROMAGNETIC RADIATION; GERM CELL TUMOR; HUMAN; HYPERTHERMIC THERAPY; INFECTION RISK; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MICROWAVE RADIATION; PHASE 2 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; TREATMENT OUTCOME; VOMITING;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY TEMPERATURE; CARCINOMA, EMBRYONAL; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; ENDODERMAL SINUS TUMOR; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; INFANT; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GERM CELL AND EMBRYONAL; RADIATION; TERATOMA; TREATMENT OUTCOME;

EID: 0032520098     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980215)82:4<793::AID-CNCR24>3.0.CO;2-S     Document Type: Article

References (43)

1. Boyle P, La Vecchia C, Maisonneuve P, Zhengt T, Macfarlane GJ. Cancer epidemiology and prevention. In: Peckham M, Pinedo UM, Veronesi U, editors. Oxford textbook of oncology. 1st edition. Oxford: Oxford University Press, Inc., 1995:199-273.
2. Gerl A, Clemm C, Lamerz R, Wilmanns W. Cisplatin-based chemotherapy of primary extragonadal germ cell tumors. A single institution experience. Cancer 1996; 77:526-32.
3. Einhorn LH. Testicular cancer as a model for curable neoplasm. Cancer Res 1981; 41:3274-80.
4. Einhorn LH. Chemotherapy of disseminated germ cell tumors. Cancer 1987; 60:570-3.
5. Pont J, Albrecht W, Portner G, Seidner F, Angel K, Hostl W. Adjuvant chemotherapy for high-risk clinical stage I non-seminomatous testicular germ cell cancer: longterm results of a prospective trial. J Clin Oncol 1996; 14:441-8.
6. Farhat F, Culine S, Bekradda M, Tierre-Lacombe MJ, Droz JP. Cisplatin and ifosfamide with either vinblastine or etoposide as salvage therapy for refractory or relapsing germ cell tumor patients. The Institute Gustave Roussy experience. Cancer 1996; 77:1193-7.
7. Pinkerton CR, Pritchard J, Spitz L. High complete response rate in children with advanced germ cell tumors using cisplatin-containing combination chemotherapy. J Clin Oncol 1986; 4:194-9.
8. Mann JR, Pearson D, Barrett A, Raafat F, Barnes JM, Wallendszus KR. Results of the United Kingdom Children's Cancer Study Group's malignant germ cell tumor studies. Cancer 1989; 63:1657-67.
9. Ablin A, Krailo M, Ramsey NK, Malogolowkin MH, Isaacs H, Raney RB, et al. Results of treatment of malignant germ cell tumors in 93 children. A report of the Children's Cancer study group. J Clin Oncol 1991; 9:1782-92.
10. Göbel U, Calaminus G, Teske C, Bamberg M, Bökkerink JP, Haas RJ, et al. BEP/VIP in children and adolescents with malignant non-testicular germ cell tumors. A comparison of the results of treatment of therapy studies MAKEI 83/86 and 89P/89. Klin Padiatr 1993; 205:231-40.
11. Bosl GJ, Vogelzang NJ, Goldman A, Fraley EE, Lange PH, Levitt SY, et al. Impact of delay in diagnosis on clinical stage of testicular cancer. Lancet 1981; 2:970-3.
12. Williams SD, Stableim DM, Einhorn LH, Muggia FM, Weiss RB, Donohue JP, et al. Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med 1987; 317:1433-8.
13. Chilvers CED, Sounders M, Bliss JM, Nicholls J, Horwich A. Influence of delay in diagnosis on prognosis in testicular cancer. Br J Cancer 1989; 59:126-8.
14. Lack EE, Travis WD, Welch KJ. Retroperitoneal germ cell tumors in childhood. A clinical and pathologic study of 11 cases. Cancer 1985; 56:602-8.
15. Motzer RJ, Mazumdar M, Bosl GJ, Bajorin DF, Amsterdam A, Vlamis V. High dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity. J Clin Oncol 1996; 14:1098-105.
16. Pratt CB, Hayes A, Green AA, Ewans WE, Senzer N, Howarth LB. Pharmacokinetic evaluation of cisplatin in children with malignant solid tumors: a phase II study. Cancer Treat Rep 1989; 7:932-9.
17. Cavaliere R, Giocatto FC, Giovanella BC, Heidelberger C, Johnson RO, Margotti M, et al. Selective heat sensitivity of cancer cells: biochemical and clinical studies. Cancer 1967; 20:1351-81.
18. Stehlin JS. Hyperthermic perfusion with chemotherapy for cancer of the extremities. Surg Gynecol Obstet 1969; 129:305-8.
19. Sapozink MD, Gibbs FA, Egger MJ. Regional hyperthermia for clinically advanced deep-seated pelvic malignancy. Am J Clin Oncol 1986; 9:162-9.
20. Issels RD, Prenninger SW, Nagele A, Boehm E, Sauer H, Jauch KW, et al. Ifosfamide plus etoposide combined with regional hyperthermia in patients with locally advanced sarcomas. A phase II study. J Clin Oncol 1990; 8:1818-29.
21. Oleson JR, Dewirst DVM, Harrelson JM, Leopold KA, Samulski TV, Tso CY. Tumor temperature distributions predict hyperthermia effect. Int J Radiat Oncol Biol Phys 1989; 6:559-70.
22. Sapareto SA, Deway WC. Thermal dose determination in cancer therapy. Int J Radiat Oncol Biol Phys 1984; 10:787-800.
23. Oleson JR, Samulski TV, Leopold KA, Scott TC, Dewirst MW, Dodge RK, et al. Sensitivity of hyperthermia trial outcomes to temperature and time: implications for thermal goals of treatment. Int J Radiat Oncol Biol Phys 1993; 25:289-97.
24. Hahn GM. Potential for therapy of drugs and hyperthermia. Cancer Res 1979; 39:2264-8.
25. Overgaard J. The current and potential role of hyperthermia in radiotherapy. Int J Radiat Oncol Biol Phys 1989; 16:535-49.
26. Di-Filippo F, Calabro A, Giannarelli D, Carlini S, Cavaliere F, Moscarelli F, et al. Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion. Cancer 1989; 63:2551-61.
27. Overgaard J, Gonzalez-Gonzalez D, Hulshof MCCH, Arcangeli G, Dahl O, Mella O, et al. Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicenter randomized trial by the European Society for Hyperthermic Oncology. Int J Hyperthermia 1996; 12:3-20.
28. Vernon CC, Hand JW, Field SB, Machin D, Whaley JB, van der Zee J, et al. Radiotherapy with and without hyperthermia in the treatment of superficial localized breast cancer: results from five randomized controlled trials. International Collaborative Hyperthermia group. Int J Radiat Oncol Biol Phys 1996; 35:731-44.
29. Ohne S, Siddik ZH, Kido Y, Zwelling LA, Bull JM. Thermal enhancement of drug uptake and DNA adducts as a possible mechanism for the effect of sequencing hyperthermia on cisplatin-induced cytotoxicity in L1210. Cancer Chemother Pharmacol 1994; 34:302-6.
30. Coss RA, Linnemanns WAM. Effects of hyperthermia on cytoskeleton: a review. Int J Hyperthermia 1996; 12:173-96.
31. Raaphorst GP, Heller DP, Bussey A. Thermal radio-sensitation by 41°C hyperthermia during low dose-rate irradiation in human normal and tumour cell lines. Int J Hyperthermia 1994; 2:263-70.
32. Barry MA, Behnke CA, Eastman A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol 1990; 40:2353-62.
33. Riess H, Löffel J, Wust P, Rau B, Gremmler M, Speidel A, et al. A pilot study of a new therapeutic approach in the treatment of locally advanced stages of rectal cancer: neoadjuvant radiation, chemotherapy and regional hyperthermia. Eur J Cancer 1995; 31:1356-60.
34. Fischer GA, Hahn GM. Enhancement of cisplatinum(II)diamminedichloride cytotoxicity by hyperthermia. Monogr Natl Cancer Inst 1982; 61:255-7.
35. Raaphorst GP, Doja S, Davis L, Stewart D, Ng CE. A comparison of hyperthermia cisplatin sensitization in human ovarian carcinoma and glioma cell lines sensitive and resistent to cisplatin treatment. Cancer Chemother Pharmacol 1996; 37:574-80.
36. Wondergem J, Bulger R, Strebel FR, Newman R, Travis E, Stephens L, et al. Effects of cisdiamminedichloroplatinum (II) combined with whole body hyperthermia on renal injury. Cancer Res 1988;48:440-6.
37. Romanowski R, Schött C, Issels R, Klingebiel T, Treuner T, Jürgens H, et al. Regional hyperthermia with systemic chemotherapy in children and adolescents: feasibility and clinical courses in a group of 34 intensively pretreated patients with tumours of unfavourable prognosis. Klin Padiatr 1993; 205:249-56.
38. Wessalowski R, Spaar HJ, Pape H, Willers R, Harms D, Göbel U. Successful liver treatment of a juvenile granulosa cell tumor in a 4-year-old child by regional deep hyperthermia, systemic chemotherapy, and irradiation. Gynecol Oncol 1995; 57:417-22.
39. Feldmann HJ, Molls M, Heinemann HG, Romanowski R, Stuschke M, Sack H. Thermoradiotherapy in locally advanced deep seated tumours - thermal parameters and treatment results. Radiother Oncol 1994; 26:38-44.
40. Mascarin M, Giavitto M, Zanazzo GA, Andolina M, Cova M, Accorsi E, et al. Avascular necrosis of bone in children undergoing allogenic bone marrow transplantation. Cancer 1991; 68:655-9.
41. Ashamalla HL, Thom SR, Goldwein JW. Hyperbaric oxygen therapy for treatment of radiation-induced sequelae in children. The University of Pennsylvania Experience. Cancer 1996; 77:2407-12.
42. Leopold KA, Dewirst MW, Samulski TV, Harrelson J, Tucker JA, George SL, et al. Relationships among tumor temperature, treatment time and histopathological outcome using preoperative hyperthermia with radiation in soft tissue sarcomas. Int J Radiat Oncol Biol Phys 1992; 22:989-98.
43. Cox RS, Kapp DS. Correlation of thermal parameters with outcome in combined radiation therapy-hyperthermia trials. Int J Hyperthermia 1992; 8:719-32.